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Abstract 
Meta-analysis for adverse events resulting from medical interventions has many 
challenges, in part due to small numbers of such events within primary studies. 
Furthermore, variability in drug dose, potential differences between drugs within the 
same pharmaceutical class, and multiple indications for a specific treatment, can all 
add to the complexity of the evidence base.  
This paper explores the use of synthesis methods, incorporating mixed treatment 
comparisons, to estimate the risk of adverse events for a medical intervention, while 
acknowledging and modelling the complexity of the structure of the evidence base. 
The motivating example was the effect on malignancy of three anti-TNF drugs 
(etanercept, adalimumab and infliximab) indicated to treat rheumatoid arthritis. Using 
data derived from 13 primary studies, a series of meta-analysis models of increasing 
complexity were applied. Models ranged from a straightforward comparison of anti-
TNF against non-anti-TNF controls, to more complex models in which a treatment 
was defined by individual drug and its dose. Hierarchical models to allow ‘borrowing 
strength' across treatment classes and dose levels, and models involving constraints 
on the impact of dose level, are described. 
These models provide a flexible approach to estimating sparse, often adverse, 
outcomes associated with interventions. Each model makes its own set of 
assumptions, and approaches to assessing goodness of fit of the various models will 
usually be extremely limited in their effectiveness, due to the sparse nature of the 
data. Both methodological and clinical considerations are required to fit realistically 
complex models in this area, and to evaluate their appropriateness. 
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1. Introduction 
Meta-analysis of adverse outcomes is frequently used [1-2], and is valuable because 
individual studies often lack power to detect adverse outcomes. Application of meta-
analysis methods to adverse event data is associated with a specific set of 
challenges [3], including the often infrequent occurrence of such adverse events. 
This issue is compounded when combined with issues whereby data may be 
available for similar but not identical treatments (and for different treatment 
indications). Ignoring such subtleties in the structure of the evidence base and 
pooling all ‘intervention’ vs ‘control’ data into an overall estimate would maximise the 
power of the analysis to detect an increased risk. However, this approach would 
potentially lose valuable information regarding individual treatment aspects (such as 
dose or individual drug), or the indications for treatment. This information would be 
conserved using a ‘splitting’ approach across treatments and/or indications, but the 
data would inevitably be ‘spread thinner’ across a greater number of nodes within a 
meta-analysis network. 
The aim of this paper is to explore, develop and apply evidence synthesis methods 
for the synthesis of adverse event data, drawing on recent developments in evidence 
synthesis methodology used in other contexts. Section 2 briefly reviews relatively 
recent developments in evidence synthesis (primarily under a Bayesian paradigm), 
highlighting approaches which are adopted in our modelling of adverse event data. 
Section 3 describes the motivating dataset on the use of anti-TNF drugs for 
rheumatoid arthritis and the risk of malignancy. Section 4 describes the models 
developed, with Section 5 describing the results of fitting the different models to the 
motivating dataset. Finally, Section 6 discusses how these models can be applied in 
clinical scenarios and how the appropriateness of models may be determined. 
 
2. Recent developments in evidence synthesis with potential relevance for 
adverse event synthesis  
Many recent developments in evidence synthesis methodology have used Bayesian 
approaches, as implemented using Markov Chain Monte Carlo (MCMC) techniques 
due to the flexibility offered by such an approach [4], and the ability to perform 
complex statistical modelling [5]; for these reasons, Bayesian approaches are 
implemented in the adverse event scenario considered here.  
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The Bayesian approach allows the use of ‘exact’ simulation approaches to the 
synthesis of sparse data, an advantage of which is that they circumvent the need for 
continuity corrections (adding a constant to the event numbers across all cells of the 
2 x 2 table where one arm has no events [6]), unlike many classical statistical meta-
analytical approaches.  
Furthermore, mixed treatment comparison (MTC) methods  [7–15], also referred to 
as network meta-analysis, offer great potential to model differences in intervention 
definitions, by allowing the synthesis of evidence across arbitrarily complex networks 
of treatment comparisons; such methods have been applied in a simple approach to 
adverse events analyses previously [16]. Graphical representations of evidence 
networks in relation to MTC analyses have been considered in detail [17], and the 
challenges of defining such networks [18] have been given recent consideration, 
acknowledging that alternative approaches may also be viable. The concept of 
‘connectedness' in a network of treatments is central to the application of MTC 
analysis, as it ensures that the randomisation of the primary studies is maintained 
whilst allowing inclusion of all available comparisons between treatments [16]. 
Recent extensions to MTC approaches encompass the inclusion of (fixed) covariate 
effects [19]. 
The use of hierarchical models has a long history in Bayesian methods generally; 
such models, which facilitate the implementation of assumptions of exchangeability, 
are commonly used in evidence synthesis applications [20]. The exchangeability 
assumption acknowledges potential differences between study results despite the 
fact that they cannot be explained by fixed covariate effect, thus allowing a 
‘borrowing of strength’ across studies [21], which then  allows the synthesis of 
primary studies with acknowledged differences.  Advanced application of Bayesian 
hierarchical models has also allowed constraints to be placed on the parameters to 
be estimated, an example of which acknowledges the differences in reliability of 
evidence across study types when combining RCTs and observational studies [22]. 
Hence, by considering these recent developments in evidence synthesis 
methodology, this paper brings together concepts of MTC modelling with hierarchical 
models and constraints, to address issues in adverse events meta-analysis that are 
characterised by (i) sparsity of events; and (ii) multiple treatments, which are 
connected in terms of the evidence network and may vary according to how the 
treatments are defined.
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3. Motivating dataset 
The motivating topic used in this paper is that of risk of malignancy in patients with 
rheumatoid arthritis who take anti-tumour necrosis factor (anti-TNF) drugs to 
alleviate their symptoms and modify the course of their disease. A possible 
association between anti-TNF drugs and malignancy risk has been investigated 
previously using pairwise meta-analysis methods [23–25]. The earliest of these 
meta-analyses [23] concentrated on two anti-TNFs, infliximab and adalimumab, but 
combined data across both drugs and did not consider dose effects.  This meta-
analysis purposively excluded a third anti-TNF, etanercept, which has a different 
molecular structure and mechanism of action compared with infliximab and 
adalimumab. The odds ratio (OR) for malignancy of anti-TNFs vs. placebo was 3.3, 
with a 95% confidence interval (CI) of 1.2; 9.1. When etanercept was considered 
separately in a time-to-event meta-analysis of data from trials [25], the pooled hazard 
ratio (HR) for malignancy of etanercept vs. controls (not receiving etanercept) was 
1.84 (95% CI 0.79; 4.28). These analyses provided the motivation to carry out a 
synthesis of all three drugs simultaneously, with specific interest in addressing the 
issues surrounding the effect of dose and specific anti-TNF with regard to 
malignancy risk. 
The dataset used in this paper was derived from previous reviews [23, 25] and in 
some cases, by recourse to primary sources [26–27], and is set out in Table 1. Data 
are included for six etanercept studies [28–33] – noting that Weisman et al. 2007 is 
referenced by an earlier citation (Baumgartner et al. 2004) in Bongartz et al. 2009 – 
five adalimumab studies [27, 34–37], and two infliximab studies [26, 38]. All 13 
primary studies included a non-anti-TNF arm. Studies that included no malignancy 
events in any trial arm were excluded as these studies do not provide any 
information on relative treatment effects [6]. For ease of classification of different 
treatments, the definitions of ‘low’, ‘recommended’ and ‘high’ dose of anti-TNF are 
used [24]. Over the 13 studies there were 76 malignancy events in the 7233 
participants. This breaks down to 14 in the control treatments out of 2275 
participants (0.62%), and 62 in the anti-TNF treatments out of 4958 participants 
(1.25%). Non-anti-TNF therapies were assumed to have no malignancy risk, and 
were therefore collapsed with placebo controls.  The dataset comprised six studies 
with two arms, five studies with three arms, and two studies with four arms. 
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4. Description of the models used 
4.1. Overview  
A series of random effects network meta-analyses, increasing in complexity, were 
performed. The initial random effects meta-analysis was a simple comparison 
between anti-TNF therapy and non-anti-TNF controls (Model A). This was followed 
by a network meta-analysis with each of the three anti-TNFs considered as having a 
distinct treatment effect, but synthesising across (i.e. ignoring) all doses for each 
drug (Model B). The third model was a network meta-analysis where the treatments 
were defined by dose of anti-TNF alone (i.e. regardless of the specific drug); Model 
C. Model D defined each treatment as a combination of specific anti-TNF and dose. 
Hierarchical models were then imposed over the network structure defined in Model 
D. Model E placed random effects across individual drug within each dose level (i.e. 
dose was considered to have a stronger influence on malignancy risk than drug), 
while Model F placed random effects across dose levels within each individual drug 
(i.e. drug was considered to have a stronger influence on malignancy risk than 
dose).  Finally, constraints were added to Model E, with the assumption that 
malignancy risk increased with dose of anti-TNF (Model G). All models included a 
non-anti-TNF control treatment for comparison purposes. Each model is discussed 
individually in more detail below and the results considered in Section 5. All models 
are applied to the same dataset, with treatment groupings varying according to the 
model which meant that, in some instances, data were pooled across multiple arms 
of the same study (e.g. when different doses of the same drug had been included in 
a trial, but dose was ignored in the model; we had no interest in differences in 
administration regime if the overall dose was the same for each regime, and this 
approach simplified the analyses and reduced the likelihood of an arm with zero 
events). In this dataset, every study had a control arm in which no anti-TNF 
treatment was given, although the methodology which follows is still relevant in the 
broader context where there is no common arm across all studies, but the network is 
connected (all nodes are directly linked to at least one other node in the network, i.e. 
by having both nodes present in the same study, and all nodes are connected to all 
other nodes, either directly, or indirectly via one or more intermediate nodes). 
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4.2. Model A: Pairwise meta-analysis comparing anti-TNFs with non-anti-TNF control 
The simplest analysis considered is a straightforward pairwise comparison, defining 
treatments as being either ‘anti-TNF’ or ‘non-anti-TNF’ and thus treating each study 
as providing the same two-group comparison. Figure 1a displays the classification of 
treatments graphically in the form of a network diagram; a format which will become 
more informative for the analysis of the more complex networks which follow. This 
allows a standard (pairwise) random effects meta-analysis model to be fitted to the 
data [39]: 
   k = 1, 2 and j = 1, 2, …, N studies      
                              [1] 
, 
where  is the number of events that have occurred out of a total of  patients 
randomised to treatment-arm k of trial j. These are assumed to be sampled from a 
binomial distribution with underlying true event probability .  Thus is the true 
log-odds of an event for treatment k = 1  (in this case the non-anti-TNF control), δj  is 
the true trial-specific log-odds ratio of the active treatment (k = 2) relative to 
treatment k =1 in the jth trial. The trial-specific log-odds are assumed to be 
generated from a normal distribution with mean d and variance σ
2, which is the 
standard random effects assumption. Vague prior distributions for the unknown 
parameters are specified as: 
. 
 
This model can be thought of as a special two-treatment case of the more general 
network meta-analysis model presented in the next section. For this model, and all 
subsequent models, in order to produce an absolute goodness of fit statistic for the 
model, the deviance for each datapoint is calculated. This deviance can then be 
summed and compared to the total number of datapoints. The fitted value for each of 
i datapoints is given by: 
                                 [2] 
These are then used to calculate the deviance for each datapoint via [40]: 
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These deviances are summed to give the overall sum of deviance.To provide a 
contrast with the Bayesian pairwise analysis, an equivalent frequentist random 
effects meta-analysis [41] was also performed, using Stata v.12.  
 
4.3. Model B: Network meta-analysis comparing individual anti-TNFs with non-anti-
TNF control 
A network meta-analysis model is applied to the dataset, in which each drug (i.e. 
etanercept, adalimumab and infliximab) is treated distinctly, but different dose levels 
are ignored. A network diagram for this four node model is shown in Figure 1b. This 
model has been described in depth [10, 42] and is outlined below. A standard mixed 
treatment random effects model with a binary outcome can be specified. Suppose 
that K treatments (where ) are being compared in a meta-analysis of j 
= 1, 2, …., N trials, and treatment 1 (non-anti-TNF in this case) is taken to be the 
reference or baseline treatment in the analysis. Let the number of events, , that 
have occurred out of a total of  patients randomised to treatment-arm k of trial j, 
be sampled from a binomial distribution with underlying true event probability .  
Thus, the likelihood of an event and the logistic regression model are the same as 
those in Model A, but here it involves K rather than 2 treatments:  
arm-level likelihood:     
 
, 
where is the true log-odds of an event in baseline treatment b in trial j, δjbk  is the 
true trial-specific log-odds ratio of treatment k relative to treatment b,  
, and d11 = 0. 
The trial-specific log-odds are assumed to be normally distributed with mean dbk and 
variance σ2 under a homogenous variance assumption [7, 19]. As before, vague prior 
distributions are specified for all unknown parameters: 
  . 
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4.4. Model C: Network meta-analysis comparing dose of anti-TNF with non-anti-TNF 
control 
Model C changes the intervention definitions used compared to Model B by not 
distinguishing between the different anti-TNF drugs, but categorising by dose level, 
defined as recommended, low and high doses. The resulting evidence network is 
presented in Figure 1c. As some of the primary studies trialled multiple doses, three 
or more distinct treatment regimes exist for certain studies, whereas in models A and 
B, multiple active treatment arms could always be pooled, as no trial compared two 
or more anti-TNFs.  This means multiple, correlated, comparisons were available for 
some studies, hence the network meta-analysis model required adjustment to 
account for this correlation [21]. Multi-arm trials introduce a correlation between each 
pair (  k≠h, of ½ and a covariance of   for homogeneous variance models 
[10, 42]. Thus, the correlated treatment effects in multi-arm trials, with p distinct 
arms, are assumed to be sampled from a multivariate (MVN) normal distribution 
given by Equation (3). The model is fitted in WinBUGS by decomposing the MVN as 
a series of conditional univariate distributions [7, 42] as in Equation (4). 
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The MTC model specified above assumes prior independence 
between  parameters [7], with the  parameters  treated as fixed 
nuisance parameters.  
This model is first in the series to introduce loops into the model; in this model, there 
are seven loops in total, four with three nodes and three with four nodes. Hence, the 
possibility of inconsistency [12] within the model is encountered for the first time. 
 
 
 
 (3) 
 (4) 
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4.5. Model D: Network meta-analysis comparing active treatments defined by dose-
drug combination with non-anti-TNF control 
Model D distinguishes distinct intervention nodes by the combination of specific anti-
TNF used and its dose (e.g. infliximab at high dose); all active interventions were 
compared against a non-anti-TNF control, as in previous models. The network used 
for this analysis is presented in Figure 1d. As some trials contributed more than two 
‘arms’ to the analysis, the network model that accounts for multi-arm trials was 
utilised, as described for Model C above. As with Model C, Model D includes 
treatment loops, hence there is a possibility for inconsistency within the model (also 
applying to Models E, F and G, which are based on the same treatment network). In 
Model D, there are nine loops in total, six with three nodes and three with four nodes.  
 
4.6. Model E: Network meta-analysis, assuming exchangeability of individual anti-
TNF drug across dose level 
The use of random effects models to assume exchangeability between treatment 
effects from multiple studies has a long history in evidence synthesis [4]. Very 
recently, exchangeability has also been assumed across certain nodes in a network 
meta-analysis [43],  which we also consider here.  
In Model E, we define treatment nodes by both drug and dose, in exactly the same 
way as for Model D. However, Model E makes the assumption that the specific dose 
has a stronger influence on malignancy risk than the specific drug that defines an 
individual ‘treatment’, whereas in Model D, drug and dose combined to create an 
individual treatment, with no assumptions regarding the relative strength of influence 
of either drug or dose on malignancy risk. Hence, using Model E, information within a 
dose level is ‘exchangeable’ across drugs, thus allowing ‘borrowing of strength’ 
across a dose level.   
The additions to Model D that are required to implement the exchangeability 
assumptions are formally outlined below:  
 (5) 
where ,  and  are the population log-odds ratios for low, 
recommended and high doses of anti-TNF respectively, and  is the between-
estimate variance of study results within each of the three doses. The degree of 
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heterogeneity within the dose levels is assumed to be equal for each of the three 
levels, due to the sparsity of the data. Vague prior distributions were placed on these 
new parameters: 
   
 
 
4.7. Model F: Network meta-analysis, assuming exchangeability of different dose 
levels within individual anti-TNF drug 
Model F is of the same format as Model E, but here it is assumed that the individual 
anti-TNF drugs have a stronger influence on malignancy risk compared to dose. 
Hence, this model incorporates exchangeability of information across dose level 
within anti-TNF drug, allowing ‘borrowing of strength’ across an individual anti-TNF 
drug. Formally: 
 (6) 
where ,  and  are the population log-odds ratios for 
etanercept, adalimumab and infliximab, and  is the between-estimate variance 
of study results within each of the three drugs. As for Model E, heterogeneity within 
the (drug) levels is assumed to be equal for each of the three levels, due to the 
sparsity of the data. The following vague priors are specified: 
   
. 
 
4.8. Model G: Applying constraints on the effect of dose to Model E 
The hierarchical network meta-analysis model was extended further by placing 
constraints on parameters in the model. The network meta-analysis model in which 
dose is considered to have a stronger association with malignancy risk (Model E), 
leading to the assumption that information on individual anti-TNF drugs is 
exchangeable within dose, is developed further, by specifying constraints that 
enforce the assumption that the effects of lower anti-TNF doses on risk of 
malignancy cannot be greater than those of higher doses: 
                                                              (7) 
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To achieve this, the prior distributions placed on each dose level were truncated to 
ensure that only higher values for the log-odds ratio of malignancy (compared with 
the non-anti-TNF control group) could be sampled for each dose level compared with 
the dose level immediately below it. Using recommended dose as the baseline, as 
this dose was present across all three anti-TNFs, the log-odds ratio for malignancy in 
the low and high doses were set to be related to the log-odds ratio for the 
recommended dose, by addition of a difference factor for each dose. The difference 
factor for the log-odds ratio comparing the low with recommended dose was then set 
to be negative, based on a half-normal distribution truncated to be below zero; 
similarly, the difference factor for the log-odds ratio for the high dose compared with 
the recommended dose was set to be positive (truncated above zero). The changes 
required to Model E to implement these constraints are presented below: 
                                           (8) 
 
where  and  are the differences in the log-odds ratios between low and 
recommended doses,  and high and  recommended doses, respectively; I(,0) 
indicates that the normal distribution is truncated above zero (can take only negative 
values); and I(0,) indicates that the normal distribution is truncated below zero (can 
take only positive values). 
 
4.9. Implementation in WinBUGS 
All models were implemented using WinBUGS v.1.4.3. Three chains with different 
initial values were used for each model, with assessment for convergence using the 
Brooks–Gelman–Rubin method [44], as well as visual inspection of the trace. 
Convergence was confirmed prior to the selection of an adequate burn-in period 
which was always at least 10,000 iterations. Following burn-in, at least 50,000 
iterations were performed to provide the results for each model. The WinBUGS code 
used for the most complex model, Model G, is provided in Appendix A. Highest 
posterior density (HPD) credible intervals (CrIs) were derived using the boa package 
[45] for R. 
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4.10. Sensitivity analysis to choice of prior distributions 
In all the analyses presented above, with the exception of the constraints specified in 
Model G, all prior distributions were intended to be vague. Our desire is for all such 
prior distributions to have minimal impact on the modelling, indeed a Bayesian 
analysis in WinBUGS was utilised because it provides the flexibility to fit the desired 
models, rather than due to the ability of such analyses to include external information 
(although in some contexts this may be advantageous). While very vague priors can 
be placed on location parameters, such as those specified on the log-odds ratios, 
previous work [46] has highlighted the difficulties in achieving this for scale 
parameters, such as variance components for random effects where data are limited, 
i.e. where there are few estimates (studies) contributing to the estimation of random 
effects. Due to this, we believe it is necessary to check robustness of estimation to 
the specification of such priors.  To this end, we conducted a sensitivity analysis 
changing all priors on random effects standard deviations from Uniform(0, 2) to half-
Normal(0, 1), i.e. a normal distribution truncated above 0; also, we placed Inverse-
Gamma(0.001, 0.001) distributions on the variance for models B, E, F and G (where 
multiple random effects were specified, some of which were informed by small 
numbers of studies). 
 
5. Results 
Table 2 presents all the relative treatments effects, compared with control, for each 
of the anti-TNF treatment categories as defined by each of the models. The overall 
mean sum of deviance(s), in conjunction with the number of datapoints, are set out 
in Table 3. The assessment of model fit, based on comparing the sum of deviances 
with the number of datapoints (which varies across models due to the merging of 
arm data for some trials in some models) suggested all models would appear to be a 
good fit to the data, and thus has little discriminatory ability. This is probably due to 
the fact that there is relatively little information in the data on which the evaluation is 
based, due to the sparseness of events, and thus highlights a universal problem 
when analysing sparse data. Furthermore, in a random effects analysis, the 
heterogeneity parameter can increase to accommodate wide variation in effects 
across studies.  
Model A provided evidence that anti-TNFs are associated with higher risk of 
malignancy than non-anti-TNF controls (OR 2.48, 95% credible interval (CrI) 1.19; 
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7.35), but, due to the model specification, was unable to provide insight as to 
whether the risk was different across anti-TNFs and/or dose levels. The equivalent 
random effects frequentist meta-analysis yielded contrasting results: OR 1.52, 95% 
CI 0.86; 2.67. These dissimilar results are due to (i) the inclusion of a continuity 
correction of 0.5 for all studies with zero events in one arm (a smaller continuity 
correction of 0.05 yielded similar results to those derived by use of 0.5); and (ii) the 
application of a prior distribution to the between-studies heterogeneity in the 
Bayesian model – although non-informative, such a distribution may impact on the 
posterior distribution of the between-studies standard deviation.  Model B, which 
estimated the risk for each anti-TNF separately, indicated that all three drugs exhibit 
a higher risk of malignancy than the non-anti-TNF control groups, although there was 
considerable uncertainty around all three estimates with the CrIs including an OR of 
1 in each instance. 
The third model, Model C, provided estimates for each dose level, ignoring specific 
anti-TNF effects. This model was illuminating because the OR for the high dose 
group was elevated considerably (OR 7.36, 95% CrI 1.94; 39.95), indicating at least 
a doubling of risk of malignancy for the high dose anti-TNF compared with controls. 
This was in contrast to the recommended and low dose treatments, for both of which 
an OR of approximately 2 (compared with non-anti-TNF controls) was estimated, 
with a CrI including 1 in both cases. 
Model D defined the treatments by both dose and specific anti-TNF, resulting in a 
potential of nine different treatment combinations (three drugs and three dose 
levels), of which seven had observed data from the available trials. However, this 
degree of resolution for the treatment definitions, in conjunction with the sparsity of 
data, resulted in very wide credible intervals, making it difficult to discern whether 
any specific anti-TNF/dose combination was associated with greater malignancy risk, 
with all CrIs including an OR of 1. Notably, the ordering of the point estimates for 
doses within drugs was consistent with that expected for a dose–response 
relationship.  
The motivation for Models E and F, which make the assumption of exchangeability 
across certain treatment categorisation factors, was to try and reduce uncertainty in 
treatment effects, through borrowing strength across units in the hierarchy, while still 
being able to estimate distinct drug/dose combinations. Thus, these models can be 
seen as a ‘half-way house’ between the assumptions made in models B and C, 
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which pool across doses and drugs respectively, and model D, which allows 
estimation of each drug/dose combination independently. 
The impact on the estimation of the treatment effects is somewhat predictable for 
both of these models. In each case there is a degree of shrinkage across the 
treatment groups assumed to be exchangeable. For example, with Model E, within 
each dose, the treatment effects for each individual drug became more similar, 
compared with the equivalent treatment effects for Model D. For completeness, the 
parameter estimates for the random effects relating to dose (Models E and G) and 
drug (Model F) are given in the Appendix in Table A1. The standard deviation across 
doses (Model E; 0.361, 95% highest posterior density (HPD) CrI 0.0008; 1.152) was 
very similar to that across drugs (Model F; 0.352, 95% HPD CrI 5.0 e-5; 1.187). For 
Model F, the three levels of dosage were shrunk towards each other within each 
drug (in comparison with Model D). In addition, for both Models E and F, the 
uncertainty, and thus the width of the CrIs, was also reduced throughout. While the 
estimated median treatment effect for each drug/dose combination remained 
elevated in both models E and F, the CrI for high dose infliximab no longer included 
an OR of 1, despite the point estimate being considerably reduced (the OR of 10.00 
from Model D was reduced to 3.75 and 3.17 in Models E and F respectively). Based 
on the sum of deviances (Table 3), Model E appeared to be a fractionally improved 
fit to the data over Models D and F, perhaps supporting (although very weakly) the 
notion that dose has a stronger influence on malignancy risk than individual drug. 
Model G modified Model E by placing constraints on the effect of drug dose, 
enforcing the assumption that lower doses cannot have higher risks of malignancy 
(in terms of the log-odds ratio compared with non-anti-TNF controls) associated with 
them. These constraints made the differences between dose levels more 
pronounced; although conclusions remain similar to previous models, with all 
treatment/dose combinations having inflated ORs, using this model, the CrIs for high 
doses of both infliximab and adalimumab did not include an OR of 1. 
Table A2 in the appendix presents the results of the sensitivity analyses where the 
prior distributions were changed on all variance components in models B, E, F and 
G, to ascertain the influence of such prior specifications on parameter estimation. 
These analyses demonstrated that the prior distributions used do indeed have some 
influence on parameter estimation; we would suggest the differences are not of a 
magnitude that would influence the overall conclusions of any of the analyses. 
16 
 
6. Discussion 
In this paper we have outlined a number of network meta-analysis models for 
estimating the risk of adverse events. Sparse data has been shown to be challenging 
for standard pairwise meta-analysis in the past, especially if there were no events at 
all in some studies or no events in at least one treatment arm within a study [6].  The 
analyses presented here demonstrate the range of potential models available; at one 
extreme are models that are unrestricted in terms of making assumptions regarding 
treatment effects according to different treatment parameters (such as drug and 
dose in Model D), for which the parameter estimates are very uncertain; at the other 
extreme are models which explicitly make stronger assumptions through expressions 
of exchangeability (Models E and F) and the addition of constraints on parameter 
estimation (Model G). Although there may be concerns that these approaches are 
overly complex, and make too many strong assumptions, it is important not to forget 
that a simple pairwise meta-analysis of this data (Model A), which implicitly assumes 
all treatments (in this example all combinations of individual drug and dose) to have 
exactly the same effect, does in fact make the strongest assumptions of all the 
models presented here. 
It is very difficult to answer the question of how strong the assumptions should be 
(and therefore which approach to modelling should be used) in any particular clinical 
context. We have shown here and elsewhere that usual approaches to establishing 
best fitting models are problematic in a sparse data context [6]. In this paper, global 
measures of fit had very little discriminatory value, and relying on statistical 
significance of model parameters will often be inappropriate due to the often low 
power of the analysis. Previous simulation work showed that, in a frequentist 
paradigm, between-study variance parameters will be estimated as zero even when 
the data have been simulated from a scenario with considerable heterogeneity [6]; 
this suggests that informative prior distributions for variance components in these 
models would be advantageous [21] and circumvent problems that the (unintended) 
influence of intentionally vague prior distributions can have [46]. The use of multiple 
models making different assumptions, as done here in the form of a sensitivity 
analysis, is possibly the most sensible approach to address these issues.  
Alternatively, prior distributions that are empirically based and informative have been 
proposed for the heterogeneity parameter [47], although not specifically with regard 
to adverse events or sparse data. Heterogeneity was seen to be considerably higher 
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for Models B and D. This reflects the fact that in these models the nodes were 
defined by the individual anti-TNF only, without reference to dose, the more 
dominant factor in influencing malignancy risk (Model B), or by anti-TNF and dose 
(Model D), but without any specific modelling to impose any form of exchangeability 
across anti-TNFs/doses (as in Models E, F and G). 
A simple solution to these problems would be simply to collect more data so that 
sparseness (in terms of number of events and numbers of trials) becomes less of an 
issue. However, this will often be time-consuming, costly, and potentially unethical in 
some contexts. As an alternative to further research, it may be possible to extend the 
potential number of trials that provide data of relevance to the clinical issue, for 
example by including data from trials where a specific intervention is used for 
indications other than those directly of interest. In the motivating example considered 
here, data were derived from studies using anti-TNF drugs to treat rheumatoid 
arthritis, but these drugs are licensed for other conditions, so data may be available 
from trials of anti-TNFs used for other indications. Data derived from trials for 
different indications would not be uncritically pooled; but it would be possible to 
extend the hierarchical network models presented here to allow data from trials for 
differing interventions to be incorporated, using the methods presented here, for 
example, to allow exchangeability within indications.   A further, and less far-
reaching, extension to the modelling presented here would be to specify 
simultaneous random effects for drug and dose levels, and in a sense combine the 
modelling extensions presented in Models E and F. Such modelling would have 
similarities with synthesis approaches pioneered in the context of extrapolating 
exposure risks across both species and dose levels simultaneously [48].  However, 
this modelling approach was not pursued here due to concerns with over-
parameterising a dataset of modest size. 
Within a network meta-analysis including loops, there is a possibility of inconsistency 
of evidence. In this example, Model C, and Models D, E, F and G, all have the 
potential for inconsistency, as they include multiple loops and trials with up to four 
arms. Additional investigation into inconsistencies within the models is warranted, for 
example using techniques of node-splitting [12], but such analyses are, due to the 
mixture of multi-arm trials (i.e. trials with two, three or four arms), inherently 
technically difficult and thus beyond the scope of this paper.  
18 
 
In summary, synthesis of sparse event data presents unique challenges. Novel 
modelling approaches have been developed and applied to a dataset that 
incorporates sparsity of events. Although these approaches may be valuable in this 
context, none provide a generic solution to the issue of data sparsity. Hence, 
consideration should be given to both methodological and clinical issues in order to 
fit realistically complex and contextually appropriate models in this area. 
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Table 1. Anti-TNF rheumatoid arthritis trial data used in synthesis models.  
First author 
(Year) 
Treatment 
Anti-TNF 
regime(s)* 
Anti-
TNF 
dose 
Number 
of 
patients 
Number of 
malignancies 
Etanercept 
Ericson (1999) Control NA  NA 105 0 
” Etanercept 25mg biw Rec 111 0 
” Etanercept 10mg qw or 
25mg qw or  
10mg biw 
Low 343 2 
Moreland (1999) Control NA  NA 80 0 
” Etanercept 25mg biw Rec 78 1 
” Etanercept 10mg biw Low 76 0 
Genovese (2002) Control NA  NA 217 4 
” Etanercept 25mg biw Rec 207 5 
” Etanercept 10mg biw Low 208 5 
Combe (2006) Control NA  NA 50 0 
” Etanercept 25mg biw Rec 204 1 
Van der Heijde 
(2006) 
Control NA NA 228 1 
” Etanercept 25mg biw Rec 454 10 
Weisman(2007)/ 
Baumgartner 
(2004) 
Control NA  NA 269 2 
” Etanercept 25mg biw Rec 266 2 
Adalimumab 
Furst (2003) Control NA  NA 318 0 
” Adalimumab 40mg eow Rec 318 4 
Weinblatt (2003) Control NA  NA 62 0 
” Adalimumab 40mg eow Rec 67 0 
” Adalimumab 20mg eow Low 69 0 
” Adalimumab 80mg eow High 73 1 
Keystone (2004) Control NA  NA 200 1 
” Adalimumab 20mg qw or 
40mg eow
  
Rec 419 8 
Van de Putte 
(2004) 
Control NA  NA 110 1 
” Adalimumab 20mg qw or 
40mg eow
  
Rec 225 2 
” Adalimumab 20mg eow Low 106 1 
” Adalimumab 40mg qw High 103 1 
Breedveld (2006) Control NA  NA 257 4 
” Adalimumab 40mg eow Rec 542 6 
Infliximab 
Maini (2004) Control NA  NA 88 1 
” Infliximab 3mg/kg q8w Rec 86 1 
” Infliximab 3mg/kg q4w 
or 10mg/kg 
q8w or 
10mg/kg 
q4w 
High 254 8 
St Clair (2004) Control NA  NA 291 0 
” Infliximab 3mg/kg q8w  Rec 372 0 
” Infliximab  6mg/q8w  High 377 4 
* Key: biw: twice weekly; eow: every other week; NA: not applicable; Rec: recommended; q4w: 4-weekly; 
q8w: 8-weekly; qw: weekly 
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Table 2. Odds ratios obtained from fitting models A to G (anti-TNF compared 
against non-anti-TNF control). 
Treatment Odds 
Ratio* 
95% Credible 
Interval 
(equal-tailed) 
Model  A : Pairwise meta-analysis, all anti-TNFs combined 
Anti-TNF 2.480 1.192; 7.354 
Model B : Network meta-analysis, comparing individual anti-
TNFs 
Etanercept 2.485 0.730; 13.44 
Adalimumab 2.399 0.685; 13.45 
Infliximab 6.878 0.664; 285.8 
Model C : Network meta-analysis, distinguishing only by dose 
of anti-TNF  
Low dose (Anti-TNF) 2.012 0.531; 8.627 
Recommended dose (Anti- TNF) 2.099 0.961; 5.455 
High dose (Anti-TNF) 7.362 1.942; 39.95 
Model D : Network meta-analysis: comparing active treatments 
defined by dose–drug combination  
Etanercept – low dose 2.279 0.378; 19.42 
Etanercept – recommended dose 2.423 0.627; 12.64 
Adalimumab – low dose 1.336 0.035; 30.91 
Adalimumab – recommended 
dose 
2.253 0.595; 12.95 
Adalimumab – high dose 4.110 0.275; 85.83 
Infliximab – recommended dose 0.881 0.016; 47.71 
Infliximab  - high dose 10.00 0.948; 393.3 
Model E : Network meta-analysis, assuming exchangeability of 
anti-TNF drugs within dose levels 
Etanercept – low dose 2.311 0.761; 8.145 
Etanercept – recommended dose 2.288 0.936; 6.620 
Adalimumab – low dose 2.290 0.484; 9.398 
Adalimumab – recommended 
dose 
2.255 0.938; 6.665 
Adalimumab – high dose 3.170 0.927; 16.55 
Infliximab – recommended dose 1.965 0.453; 6.973 
Infliximab  - high dose 3.753 1.253; 23.02 
Model F : Network meta-analysis, assuming exchangeability of  
dose levels within anti-TNF drugs 
Etanercept – low dose 2.323 0.795; 8.198 
Etanercept – recommended dose 2.369 0.954; 7.253 
Adalimumab – low dose 2.280 0.501; 9.194 
Adalimumab – recommended 
dose 
2.299 0.914 ; 7.315 
Adalimumab – high dose 2.538 0.776; 12.20 
Infliximab – recommended dose 2.109 0.398; 9.309 
Infliximab  - high dose 3.167 1.061; 23.08 
Model G : Applying constraints on the effect of dose to Model 
E 
Etanercept – low dose 1.440 0.401; 5.027 
 
Etanercept – recommended dose 2.170 0.865; 6.650 
 
Adalimumab – low dose 1.313 0.212; 5.933 
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Adalimumab – recommended 
dose 
2.275 0.915; 7.323 
 
Adalimumab – high dose 6.711 1.449; 48.58 
 
Infliximab – recommended dose 2.048 0.426; 8.716 
 
Infliximab  - high dose 8.311 2.060; 67.40 
 
 * Median of samples from posterior distribution
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Table 3. Goodness of model fit statistics for models A to G.  
Model 
Between study 
standard 
deviation – i.e. 
heterogeneity 
parameter: 
median (95% 
highest posterior 
density credible 
interval) 
Sum of 
deviance: 
mean  
(number of 
data points) 
A 
0.583 (0.0005; 
1.558) 
24.14 (26) 
B 
0.802 (4.0 e-5; 
1.775) 
25.06 (26) 
C 
0.548 (0.0003; 
1.485) 
32.41 (35) 
D 
0.862 (0.007; 
1.811)  
34.28 (35) 
E 
0.550 (0.0002; 
1.460) 
33.13 (35) 
F 
0.550 (0.0003; 
1.489) 
33.61 (35) 
G 
 0.590 (0.001; 
1.541) 
32.67 (35) 
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Appendix A. WinBUGS code for Model G.  
# ================================= 
# Notes 
# 13 trials (6 with 2 arms,  5 with 3 arms, 2 with 4 arms, 35 arms total),  
# 35 data points, 
# 8 treatments:  
 
# i indexes datapoints 
# j indexes trials 
# k indexes treatments   
 
#Treatments coding: 
# 1: Placebo and/or DMARD 
# 2: Etanercept Recommended 
# 3: Etanercept Low 
# 4. Adalimumab Recommended 
# 5. Adalimumab Low 
# 6. Adalimumab High 
# 7. Infliximab Recommended 
# 8. Infliximab High 
 
# ================================== 
 
model{ 
for(i in 1:NS){  
w[i,1] <-0 
delta[i,t[i,1]]<-0 
 mu[i] ~ dnorm(0,.0001)            # vague priors for trial baselines 
 for (k in 1:na[i])  {  
  r[i,k] ~ dbin(p[i,t[i,k]],n[i,k])                  # binomial likelihood 
  logit(p[i,t[i,k]])<-mu[i] + delta[i,t[i,k]] }                                                              
 
# model 
       for (k in 2:na[i]) { 
                   delta[i,t[i,k]] ~ dnorm(md[i,t[i,k]],taud[i,t[i,k]])          
md[i,t[i,k]] <-  d[t[i,k]] - d[t[i,1]]  + sw[i,k]                    
                    taud[i,t[i,k]] <- tau *2*(k-1)/k                                     
                    w[i,k] <- (delta[i,t[i,k]]  - d[t[i,k]] + d[t[i,1]]) #adjustment, multi-arm 
RCTs 
                    sw[i,k] <-sum(w[i,1:k-1])/(k-1) }  } 
for(i in 1:NS){  
      for (k in 1:na[i]){  
         #Deviance residuals for data i                                                                                        
       rhat[i,k] <- (p[i,t[i,k]] * n[i,k])                                                                                                           
    dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))  +  (n[i,k]-r[i,k]) * (log(n[i,k]-
r[i,k]) - log(n[i,k]-rhat[i,k])))  } 
sumdev[i] <- sum(dev[i,1:na[i]])   }             
   ssumdev <- sum(sumdev[]) 
d[1]<-0 
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#D.d[1] refers to recommended dose, D.d[2] refers to low dose, D.d[3] refers to high 
dose 
 
d[2]~dnorm(D.d[1], prec.d) 
d[3]~dnorm(D.d[2], prec.d) 
d[4]~dnorm(D.d[1], prec.d) 
d[5]~dnorm(D.d[2], prec.d) 
d[6]~dnorm(D.d[3], prec.d) 
d[7]~dnorm(D.d[1], prec.d) 
d[8]~dnorm(D.d[3], prec.d) 
 
#  vague priors for basic parameters 
 
sd~dunif(0,2)                                             
tau<-1/pow(sd,2) 
 
prec.d<-1/(sd.d*sd.d) 
sd.d~dunif(0,2) 
 
# Constraints model for D.d  
 
D.d[2] <- D.d[1] + diff1 
D.d[3] <- D.d[1] + diff2 
 
diff1 ~ dnorm(0,0.0001)I(,0) 
diff2 ~ dnorm(0,0.0001)I(0,) 
 
D.d[1] ~ dnorm(0,0.0001) 
 
pdiff1 <- 1-step(diff1) 
pdiff2 <- step(diff2) 
 
} 
 
 
# DATA 
 
# NS=no. studies;   
# NB : set up M vectors each r[,]. n[,] and t[,],  where M is the maximum number of 
# treatments per trial in the dataset. In this dataset M is 4. 
 
list(NS=13) 
 
r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] r[,4] n[,4] t[,1] t[,2] t[,3] t[,4] na[] 
1 228 10 454 NA 1 NA 1 1 2 NA NA 2 
0 50 1 204 NA 1 NA 1 1 2 NA NA 2 
0 80 1 78 0 76 NA 1 1 2 3 NA 3 
4 217 5 207 5 208 NA 1 1 2 3 NA 3 
2 269 2 266 NA 1 NA 1 1 2 NA NA 2 
0 106 0 111 2 343 NA 1 1 2 3 NA 3 
0 318 4 318 NA 1 NA 1 1 4 NA NA 2 
25 
 
0 62 0 67 0 69 1 73 1 4 5 6 4 
1 200 8 419 NA 1 NA 1 1 4 NA NA 2 
1 110 2 225 1 106 1 103 1 4 5 6 4 
4 257 6 542 NA 1 NA 1 1 4 NA NA 2 
1 88 1 86 8 254 NA NA 1 7 8 NA 3 
0 291 0 372 4 377 NA 1 1 7 8 NA 3 
END 
 
 
 
# INITIAL VALUES 
 
# d refers to number of treatments, mu refers to number of studies,  
# delta refers to number of datapoints 
 
list(d=c(NA,0.75,0.70,0.77,0.65,1.87,0.54,2.1),  mu=c(-5,-7,-7,-4,-5,-7,-6,-7,-5,-6,-4,-5,-
7),sd=0.7,sd.d=0.6, D.d=c(0,NA,NA),diff1=-1,diff2=1, 
delta = structure(.Data=c( 
            NA,1, NA, NA, NA, 
            NA, NA, NA, NA, 0.8, 
            NA, NA, NA, NA, NA, 
            NA, NA,1.0, 0.6, NA, 
            NA, NA, NA, NA, NA, 
0.5, 0.5, NA, NA, NA, 
            NA, NA, NA, 0.7, NA, 
            NA, NA, NA, NA, NA, 
            NA, 0.7, 0.9, NA, NA, 
            NA, NA, NA, NA, NA, 
            NA, 1.2, NA, NA, NA, 
            NA, NA, NA, NA, 0.7, 
0.6, 2.0, NA, NA, NA, 
            NA, NA, 0.9, NA, NA, 
            NA, NA, NA, NA, NA, 
0.7, 0.5, 1.5, NA, NA, 
            NA, NA, NA, 0.3, NA, 
            NA, NA, NA, NA, NA, 
            NA, NA, NA, NA, 0.4, 
1.86, NA, NA, NA, NA, 
            NA, NA,0.5,2.4), 
.Dim = c(13,8))) 
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Table A1. Dose and drug random effect parameter estimates from Models E, F 
and G. 
Model Parameter 
Median (95% Credible 
Interval)1 
E  2.389 (0.691 to 8.950) 
  2.259 (0.813; 6.931) 
  3.135 (1.046; 15.25) 
  0.361 (0.0008; 1.152)* 
F  2.380 (0.808; 8.277) 
  2.391 (0.796; 8.539) 
  2.515 (0.749; 11.84) 
  0.352 (5.0 e-5; 1.187)* 
G  1.228 (0.232; 3.948) 
  2.274 (0.802; 7.989) 
  7.758 (1.984; 64.54) 
  0.394 (0.0008;  1.409)* 
1
Credible interval is equal-tailed unless indicated by * (highest posterior density interval).
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Table A2. Results of sensitivity analysis changing the prior distributions 
placed on variance parameters. 
 Prior Distributions on Variance Components 
Treatment 
effect/parameters 
Standard 
Deviations  
~ Uniform(0,2) 
Standard Deviations  
~ Half-Normal(0,1) 
Variances 
 ~ Inverse-
Gamma(0.001,0.001) 
Model B : Network meta-analysis, comparing individual anti-TNFs 
 Odds 
Ratio
1
 
95% 
CrI
2 
Odds 
Ratio
1
 
95% CrI
2 
Odds 
Ratio
1
 
95% 
CrI
2 
Etanercept 2.485 0.730; 
13.44 
2.353 0.797; 
10.22 
2.302 0.828; 
10.87 
Adalimumab 2.399 0.685; 
13.45 
2.264 0.735; 
10.39 
2.134 0.758; 
10.82 
Infliximab 6.878 0.664; 
285.8 
6.054 0.741; 
174.4 
5.998 0.785; 
273.3 
       
 Median 95% 
CrI
3 
Median 95% CrI
3 
Median 95% 
CrI
3 
 
0.802 4.0 e-5; 
1.775 
0.590 0.0003; 
1.513 
0.313 0.013 ; 
1.690 
Model E : Network meta-analysis, assuming exchangeability of different anti-TNF 
drugs within dose levels  
 Odds 
Ratio
1
 
95% 
CrI
2 
Odds 
Ratio
1
 
95% CrI
2 
Odds 
Ratio
1
 
95% CrI
2 
Etanercept – low 
dose 
2.311 0.761; 
8.145 
2.320 0.830; 
7.123 
2.178 0.904; 
5.432 
Etanercept – 
recommended 
dose 
2.288 0.936; 
6.620 
2.284 1.002; 
6.005 
2.143 1.068; 
4.902 
Adalimumab – low 
dose 
2.290 0.484; 
9.398 
2.349 0.644; 
8.269 
2.169 0.772 ; 
6.061 
Adalimumab – 
recommended 
dose 
2.255 0.938; 
6.665 
2.231 0.974; 
6.036 
2.099 0.997; 
4.791 
Adalimumab – high 
dose 
3.170 0.927; 
16.55 
3.053 1.055; 
13.67 
2.538 1.059; 
8.692 
Infliximab – 
recommended 
dose 
1.965 0.453; 
6.973 
1.977 0.519; 
6.090 
1.979 0.664; 
4.870 
Infliximab  - high 
dose 
3.753 1.253; 
23.02 
3.472 1.292; 
17.57 
2.774 1.251; 
11.21 
       
 2.389 0.691; 
8.950 
2.397 0.814;7.611 2.205 0.919; 
5.759 
 2.259 0.813; 
6.931 
2.236 0.898; 
6.126 
2.114 0.996; 
4.890 
 3.135 1.046; 
15.25 
2.991 1.126; 
12.11 
2.524 1.153; 
8.128 
       
 Median 95% 
CrI
3 
Median 95% CrI
3 
Median 95% CrI
3 
 0.361 0.0008; 
1.152 
0.313 0.0002; 
0.923 
0.170 0.014; 
0.679 
 
0.550 0.0002; 
1.460 
0.440 0.002; 
1.182 
0.192 0.014; 
0.957 
Model F : Network meta-analysis, assuming exchangeability of different dose 
levels within each anti-TNF drug 
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 Odds 
Ratio
1
 
95% 
CrI
2 
Odds 
Ratio
1
 
95% CrI
2 
Odds 
Ratio
1
 
95% CrI
2 
Etanercept – low 
dose 
2.323 0.795; 
8.198 
2.258 0.840; 
6.591 
2.174 1.016; 
5.532 
Etanercept – 
recommended 
dose 
2.369 0.954; 
7.253 
2.293 0.985; 
5.989 
2.201 1.085; 
5.377 
Adalimumab – low 
dose 
2.280 0.501; 
9.194 
2.194 0.628; 
7.771 
2.154 0.852; 
5.889 
Adalimumab – 
recommended 
dose 
2.299 0.914; 
7.315 
2.219 0.969; 
6.002 
2.157 1.061; 
5.252 
Adalimumab – high 
dose 
2.538 0.776; 
12.20 
2.390 0.796; 
9.673 
2.259 0.977; 
6.852 
Infliximab – 
recommended 
dose 
2.109 0.398; 
9.309 
2.061 0.462; 
7.488 
2.099 0.729; 
6.188 
Infliximab  - high 
dose 
3.167 1.061; 
23.08 
2.907 1.097; 
18.03 
2.533 1.137; 
10.39 
       
 2.380 0.808; 
8.277 
2.292 0.884; 
6.655 
2.199 1.056; 
5.577 
 2.391 0.796; 
8.539 
2.277 0.881; 
7.037 
2.195 1.039; 
5.641 
 2.515 0.749; 
11.84 
2.401 0.831; 
9.386 
2.276 1.015; 
6.911 
       
 Median 95% 
CrI
3 
Median 95% CrI
3 
Median 95% CrI
3 
 
0.352 5.0 e-5; 
1.187 
0.295 3.0 e-5; 
0.959 
0.146 0.013; 
0.666 
 
0.550 0.0003; 
1.489 
0.464 0.0002; 
1.194 
0.211 0.014; 
0.992 
Model G : Applying constraints on the effect of dose to Model E 
 Odds 
Ratio
1
 
95% 
CrI
2 
Odds 
Ratio
1
 
95% CrI
2 
Odds 
Ratio
1
 
95% CrI
2 
Etanercept – low 
dose 
1.440 0.401; 
5.027 
1.466 0.448; 
4.505 
1.388 0.498; 
3.632 
Etanercept – 
recommended 
dose 
2.170 0.865; 
6.650 
2.151 0.924; 
5.668 
2.051 0.988; 
4.681 
Adalimumab – low 
dose 
1.313 0.212; 
5.933 
1.342 0.288; 
5.030 
1.345 0.391; 
3.953 
Adalimumab – 
recommended 
dose 
2.275 0.915; 
7.323 
2.241 0.975; 
6.190 
2.089 1.038; 
4.851 
Adalimumab – high 
dose 
6.711 1.449; 
48.58 
6.727 1.610; 
36.15 
6.493 1.918; 
27.07 
Infliximab – 
recommended 
dose 
2.048 0.426; 
8.716 
2.055 0.525; 
7.144 
2.012 0.770; 
5.308 
Infliximab – high 
dose 
8.311 2.060; 
67.40 
7.919 2.208; 
46.23 
7.024 2.238; 
32.54 
       
 1.228 0.232; 
3.948 
1.281 0.305; 
3.701 
1.313 0.409; 
3.307 
 2.274 0.802; 2.239 0.903; 2.088 1.001; 
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7.989 6.495 5.046 
 7.758 1.984; 
64.54 
7.475 2.091; 
43.73 
6.824 2.188; 
30.46 
       
 Median 95% 
CrI
3 
Median 95% CrI
3 
Median 95% CrI
3 
 0.394 0.0008; 
1.409 
0.465 0.0005; 
1.111 
0.145 0.015; 
0.767 
 
0.590 0.001; 
1.541 
0.326 7.0 e-5; 
1.237 
0.209 0.015; 
1.035 
1
 Median of samples from posterior distribution. 
2 
Equal-tailed credible interval. 
3
 Highest 
posterior density credible interval.  
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Figure 1 Network diagrams showing categorisation of treatment 
definitions used in the various models considered (numbers on lines 
represent the total number of studies which make each comparison; 
where there is a second number, this indicates the number of studies 
within the total for which there are zero events in both groups making 
the comparison).  
 
 
 
 
 
a) Pairwise meta-analysis comparing all anti-TNF data to non-anti-TNF 
control; used in Model A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
 
 
Anti-TNF 
(Etanercept,  
Adalimumab  
or Infliximab) 
 
 
 
 
Control  
(Placebo/DMARD) 
31 
 
 
b) Network meta-analysis comparing individual anti-TNFs (combining all 
doses) with non-anti-TNF control; used in Model B. 
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c) Network meta-analysis comparing distinct dose level of anti-TNFs 
(combining individual drugs at the same dose) with non-anti-TNF 
control; used in Model C. 
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d)  Network meta-analysis comparing individual anti-TNFs/dose 
combinations with non-anti-TNF control; used in Models D, E, F and G. 
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